#United States #Bethesda #Revalesio #RNS60 #ASENT

Revalesio Unveils Advances in Stroke Treatment at ASENT Annual Meeting

Revalesio, a pioneering biopharmaceutical firm focused on neurological disorders, recently participated in the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting held on March 5, 2026. The company took center stage with its presentation on RNS60, an innovative treatment for acute ischemic stroke, highlighting its potential to not only shorten hospital stays but also enhance patient recovery outcomes.

Key Highlights from the Presentation

During the meeting, Dr. Jordan Dubow, Revalesio's Chief Medical Officer, delivered a compelling talk titled “Use of Post EVT Imaging as a Biomarker for Cytoprotection.” This presentation focused on findings from the Phase 2 RESCUE clinical trial, illustrating the significant correlation between reduced brain tissue loss and improved functional results for patients treated with RNS60 shortly after stroke onset.

The trial involved patients who underwent endovascular thrombectomy (EVT) within 12 hours of a stroke incident and received RNS60 at a high dose. Remarkably, results indicated a 50% reduction in brain tissue loss compared to conventional treatments, paving the way for a transformative approach in stroke therapy.

Integrating Imaging Biomarkers

One of the innovative aspects underscored in Dr. Dubow’s presentation was the use of early post-EVT MRI scans to establish a baseline infarct volume—this facilitates an accurate comparison of how effective various interventions are post-stroke. By quantifying stroke size in this manner, the study revealed that high-dose RNS60 led to a notable reduction in infarct growth, significantly enhancing the chances of favorable clinical outcomes measured by the Modified Rankin Scale (mRS) after 90 days.

Industry Collaboration and Expert Insights

The session gathered prominent figures in the field, including Dr. Sean Savitz and Dr. David Liebeskind, who explored the current climate of stroke therapeutics and the promising investment opportunities available for large pharmaceutical companies. Discussions emphasized the need for innovation and collaboration to address the pressing challenges in stroke care.

Dr. Dubow articulated a crucial message: “Despite advancements in EVT, patients with large vessel ischemic strokes still face substantial challenges in achieving favorable outcomes. The integration of imaging biomarkers in early clinical trials could be pivotal in identifying effective therapies that warrant progression into larger studies.”

New Findings and Their Impact

In another significant presentation, Andreas Kalmas, Revalesio's Vice President of Drug Development, shared compelling insights from a post hoc analysis of the RESCUE trial, which underscored the advantages of RNS60. According to the data:

• - Patients treated with high-dose RNS60 enjoyed an average of 4.8 days shorter hospital stays compared to those receiving standard care.
• - A staggering 55% of patients discharged after receiving RNS60 returned home, compared to just 21% of those on placebo.
• - The analysis recorded 72% of subjects achieving a positive outcome against 37% on placebo based on modified Rankin Scale assessments.

These findings suggest that RNS60 not only facilitates quicker recovery but may also be integral in reshaping the approach to acute stroke treatment.

Addressing Global Health Needs

Stroke is a leading global health crisis, carrying a high risk of long-term disability and death. Approximately 80% of ischemic stroke patients do not qualify for existing treatments, underscoring the urgent need for alternative therapeutic options. Revalesio aims to bridge this gap with RNS60, which is designed as an adjunctive therapy to existing acute interventions.

About RNS60 and Revalesio

RNS60 is distinguished by its unique composition—an oxygen-enriched saline solution known for cytoprotective and anti-inflammatory properties, supporting cellular health and function. Revalesio's ongoing commitment to advancing neurological treatment culminates in plans for a Phase 3 clinical trial aimed at solidifying the efficacy of RNS60 for acute ischemic stroke.

With promising Phase 2 results indicating improved recovery and reduced complications, the momentum for RNS60 grows as Revalesio strives to innovate and improve lives affected by stroke and other neurological conditions.

For more detailed information and updates, please visit Revalesio's website or connect with them on LinkedIn.